KPP Advisory Services LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

KPP Advisory Services LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 6.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,676 shares of the company’s stock after acquiring an additional 332 shares during the period. KPP Advisory Services LLC’s holdings in Zoetis were worth $925,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Cherry Creek Investment Advisors Inc. grew its holdings in shares of Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after acquiring an additional 58 shares during the last quarter. Grove Bank & Trust grew its holdings in shares of Zoetis by 0.5% in the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after acquiring an additional 61 shares during the last quarter. Hancock Whitney Corp grew its holdings in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after acquiring an additional 61 shares during the last quarter. Strategy Asset Managers LLC grew its holdings in shares of Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock worth $356,000 after acquiring an additional 62 shares during the last quarter. Finally, Procyon Advisors LLC grew its holdings in shares of Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after acquiring an additional 63 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $170.81 on Monday. The stock has a market cap of $77.06 billion, a price-to-earnings ratio of 32.11, a PEG ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a fifty day moving average price of $169.62 and a 200 day moving average price of $179.46.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the firm earned $1.36 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.17%. The ex-dividend date is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Morgan Stanley decreased their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.